MindWalk highlighted progress in its AI-driven asset pipeline, including advancements in its GLP1 receptor agonist program, which achieved receptor activation above semaglutide in in vitro assays. The ...

Shares of MindWalk Holdings Corp. (NASDAQ: HYFT) rose sharply in pre-market trading ahead of quarterly earnings. Wall Street expects MindWalk to report a quarterly loss of 1 cent per share on revenue ...

The latest announcement is out from MindWalk Holdings ( (HYFT)). On December 15, 2025, MindWalk Holdings reported record financial growth for the second quarter of fiscal 2026, with a 54% increase in ...

MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will host a conference call to discuss its ...

MindWalk Holdings ( (HYFT)) has shared an update. MindWalk Holdings Corp. announced that its Chief Technology Officer, Dr. Dirk Van Hyfte, will participate in a fireside chat at the AI Drug Discovery ...

MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate in a ...

MindWalk (NASDAQ: HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and wet lab operations for biologics discovery and development, today announced financial ...

MindWalk Holdings has pivoted to an asset-light, AI-driven techbio platform, leveraging its HYFT and LensAI technologies for in silico drug discovery. LensAI's early successes include a dual-action ...

MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company today announced the appointment of industry veteran Thomas W. Lynch, Ph.D. as Chief Business ...